sur Nyxoah SA. (isin : BE0974358906)
Nyxoah Reports First Quarter 2025 Financial and Operating Results
Nyxoah SA has released its financial and operating results for the first quarter of 2025, with the company anticipating FDA Pre-Market Approval (PMA) for their Genio® system in the second quarter. Key financial figures show a revenue of €1.1 million, a slight decrease from €1.2 million in the same period of 2024. The operating loss widened from €12.2 million to €20.6 million, attributed to higher R&D expenses and increased selling, general, and administrative costs.
The company completed FDA validation requirements, with the final site inspection in progress. Cash and equivalents stood at €63.0 million, down from €85.6 million at 2024 end. An FDA Approvable Letter was received, marking the Genio® system's application as meeting significant regulatory standards. Nyxoah is confident in meeting the remaining criteria soon.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Nyxoah SA.